Sanofi-Aventis Eyes Expanded Menactra Indication Following Initial Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves the meningococcal conjugate vaccine for patients 11-55 years old; Sanofi-Aventis will submit a sBLA for use in children ages 2-11 by February. The company is currently studying the vaccine in patients under age 2 and will initiate a study evaluating Menactra in subjects over age 55 years by January 2006.
You may also be interested in...
Sanofi Vaccine Sales Jump 50 Percent In Q3
Performance of vaccines business helps offset slight decline in pharmaceuticals revenues, hard hit by Ambien IR generics.
Sanofi Vaccine Sales Jump 50 Percent In Q3
Performance of vaccines business helps offset slight decline in pharmaceuticals revenues, hard hit by Ambien IR generics.
Sanofi’s Menactra Use Expanded To Children
Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.